

Tocilizumab for induction and maintenance of remission  
randomised, double-blind, placebo-controlled trial

Lancet, The

387, 1921-1927

DOI: [10.1016/s0140-6736\(16\)00560-2](https://doi.org/10.1016/s0140-6736(16)00560-2)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Giant Cell Arteritis and Polymyalgia Rheumatica: 2016 Update. Rambam Maimonides Medical Journal, 2016, 7, e0035.	0.4	39
2	Tocilizumab for polymyalgia rheumatica: a first or second line?. Annals of the Rheumatic Diseases, 2016, 75, e47-e47.	0.5	3
3	Interleukin-6: a promising target for the treatment of polymyalgia rheumatica or giant cell arteritis?. RMD Open, 2016, 2, e000305.	1.8	9
5	Recent advances in the diagnosis and treatment of polymyalgia rheumatica. Expert Review of Clinical Immunology, 2016, 12, 1037-1045.	1.3	13
6	Treating giant-cell arteritis: is IL-6 the cytokine to target?. Lancet, The, 2016, 387, 1882-1883.	6.3	7
7	Predictors of Cardiovascular Hospitalization in Giant Cell Arteritis: Effect of Statin Exposure. A French Population-based Study. Journal of Rheumatology, 2016, 43, 2162-2170.	1.0	24
8	Has the time come for biotherapies in giant cell arteritis and polymyalgia rheumatica?. Joint Bone Spine, 2016, 83, 471-472.	0.8	18
10	Managing of giant cell arteritis and polymyalgia rheumatica. Expert Opinion on Orphan Drugs, 2016, 4, 1133-1144.	0.5	6
11	Approach to giant cell arteritis and recent evidence on its relation with cardiovascular risk. A review. European Geriatric Medicine, 2016, 7, 591-596.	1.2	6
14	Moving towards new treatments for vasculitis. Expert Opinion on Emerging Drugs, 2016, 21, 239-242.	1.0	1
15	Giant Cell Arteritis. Annals of Internal Medicine, 2016, 165, ITC65.	2.0	69
18	Steroid-sparing effect and toxicity of dapsone treatment in giant cell arteritis. Medicine (United Tj ETQq1 1 0.784314 rgBT /Overlock 28)	0.4	28
19	Giant cell arteritis. Best Practice and Research in Clinical Rheumatology, 2016, 30, 169-188.	1.4	36
20	Polymyalgia Rheumatica and Giant Cell Arteritis. JAMA - Journal of the American Medical Association, 2016, 315, 2442.	3.8	346
22	A Randomized, Double-blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis. Arthritis and Rheumatology, 2017, 69, 837-845.	2.9	271
23	The Treatment of Giant Cell Arteritis. Current Treatment Options in Neurology, 2017, 19, 2.	0.7	10
24	Standard and biological treatment in large vessel vasculitis: guidelines and current approaches. Expert Review of Clinical Immunology, 2017, 13, 345-360.	1.3	29
25	An expanded population of pathogenic regulatory T cells in giant cell arteritis is abrogated by IL-6 blockade therapy. Annals of the Rheumatic Diseases, 2017, 76, 898-905.	0.5	76

#	ARTICLE	IF	CITATIONS
26	The role and therapeutic targeting of IL-6 in rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 535-551.	1.3	166
28	Update on the management of giant cell arteritis. <i>Therapeutic Advances in Chronic Disease</i> , 2017, 8, 69-79.	1.1	15
29	Giant cell arteritis: beyond temporal artery biopsy and steroids. <i>Internal Medicine Journal</i> , 2017, 47, 1228-1240.	0.5	23
30	Infections and vasculitis. <i>Current Opinion in Rheumatology</i> , 2017, 29, 17-23.	2.0	18
32	Controverse dans la corticothérapie des vascularites systémiques. <i>Revue Du Rhumatisme Monographies</i> , 2017, 84, 262-269.	0.0	3
33	Tocilizumab for giant cell arteritis with corticosteroid-resistant progressive anterior ischemic optic neuropathy. <i>Joint Bone Spine</i> , 2017, 84, 615-619.	0.8	13
34	Tocilizumab-Induced Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome in Adult-Onset Still Disease. <i>Annals of Internal Medicine</i> , 2017, 167, 141.	2.0	9
36	Myeloid-derived cells in prostate cancer progression: phenotype and prospective therapies. <i>Journal of Leukocyte Biology</i> , 2017, 102, 393-406.	1.5	55
37	Cutaneous Manifestations of Medium- and Large-Vessel Vasculitis. <i>Clinical Reviews in Allergy and Immunology</i> , 2017, 53, 452-468.	2.9	48
38	Recent advances in our understanding of giant cell arteritis pathogenesis. <i>Autoimmunity Reviews</i> , 2017, 16, 833-844.	2.5	150
39	New use for tocilizumab in giant cell arteritis. <i>Rheumatology</i> , 2017, 56, kew489.	0.9	0
40	The role of interleukin-6 signalling and its therapeutic blockage in skewing the T cell balance in rheumatoid arthritis. <i>Clinical and Experimental Immunology</i> , 2017, 189, 12-20.	1.1	65
42	Physiopathologie des artérites à cellules géantes. <i>Revue Du Rhumatisme Monographies</i> , 2017, 84, 215-222.	0.0	2
43	Abatacept as Adjunctive Therapy for the Treatment of Giant Cell Arteritis: Comment on the Article by Langford et al. <i>Arthritis and Rheumatology</i> , 2017, 69, 1504-1504.	2.9	5
44	Personalized Biologic Therapy for Large Vessel Vasculitis: Comment on the Articles by Langford et al. <i>Arthritis and Rheumatology</i> , 2017, 69, 1504-1505.	2.9	0
45	Update on systemic vasculitides. <i>Journal of Clinical Pathology</i> , 2017, 70, 476-482.	1.0	9
46	The European Vasculitis Society 2016 Meeting Report. <i>Kidney International Reports</i> , 2017, 2, 1018-1031.	0.4	21
47	Scalp necrosis of the forehead and temple region. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, 1158-1161.	0.4	0

#	ARTICLE	IF	CITATIONS
48	Giant Cell Arteritis: Current and Future Treatment Options. Current Treatment Options in Rheumatology, 2017, 3, 153-163.	0.6	0
49	Tocilizumab (Actemra). Human Vaccines and Immunotherapeutics, 2017, 13, 1972-1988.	1.4	193
50	Treatment of polyarteritis nodosa with tocilizumab: a new therapeutic approach?. RMD Open, 2017, 3, e000446.	1.8	16
51	Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities. Nature Reviews Rheumatology, 2017, 13, 578-592.	3.5	161
52	Development of a Core Set of Outcome Measures for Large-vessel Vasculitis: Report from OMERACT 2016. Journal of Rheumatology, 2017, 44, 1933-1937.	1.0	33
54	Tocilizumab â€” a new frontier for GCA therapy. Nature Reviews Rheumatology, 2017, 13, 700-701.	3.5	0
55	Biologic Agents in the Treatment of Childhood-Onset Rheumatic Disease. Journal of Pediatrics, 2017, 189, 31-39.	0.9	3
56	Current clinical evidence of tocilizumab for the treatment of ANCA-associated vasculitis: a prospective case series for microscopic polyangiitis in a combination with corticosteroids and literature review. Clinical Rheumatology, 2017, 36, 2383-2392.	1.0	36
57	Newer Therapies for Giant Cell Arteritis. Advances in Ophthalmology and Optometry, 2017, 2, 321-338.	0.3	0
58	Polymyalgia Rheumatica and Giant Cell Arteritis. , 2017, , .		1
59	Giant-Cell Arteritis â€” More Ecstasy, Less Agony. New England Journal of Medicine, 2017, 377, 385-386.	13.9	8
60	Trial of Tocilizumab in Giant-Cell Arteritis. New England Journal of Medicine, 2017, 377, 317-328.	13.9	974
61	Polymyalgia rheumatica. Lancet, The, 2017, 390, 1700-1712.	6.3	196
62	Cerebral Arteriopathies, Venous Thrombosis, and Migraine. Seminars in Neurology, 2017, 37, 339-350.	0.5	3
63	Investigational drugs in systemic vasculitis. Expert Opinion on Investigational Drugs, 2017, 26, 1049-1061.	1.9	5
65	Noninfectious aortitis. Current Opinion in Cardiology, 2017, 32, 692-698.	0.8	3
67	Visual loss and other cranial ischaemic complications in giant cell arteritis. Nature Reviews Rheumatology, 2017, 13, 476-484.	3.5	121
68	Newly diagnosed vs. relapsing giant cell arteritis: Baseline data from the GiACTA trial. Seminars in Arthritis and Rheumatism, 2017, 46, 657-664.	1.6	62

#	ARTICLE	IF	CITATIONS
69	Long-term remission in biopsy proven giant cell arteritis: A retrospective cohort study. <i>Journal of Autoimmunity</i> , 2017, 77, 39-44.	3.0	27
70	Gastrointestinal aspects of vasculitides. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017, 14, 185-194.	8.2	27
71	Superficial temporal artery aneurysm associated with immunoglobulin G4-related disease. <i>Journal of Vascular Surgery Cases and Innovative Techniques</i> , 2017, 3, 243-246.	0.3	7
72	Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patients. <i>RMD Open</i> , 2017, 3, e000570.	1.8	33
73	Kopfhautnekrose an Stirn und Schläfe. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, 1158-1161.	0.4	0
75	Protective Role of Mast Cells in Primary Systemic Vasculitis: A Perspective. <i>Frontiers in Immunology</i> , 2017, 8, 990.	2.2	6
76	Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 1593-1603.	2.0	85
77	Giant cell arteritis: pathogenic mechanisms and new potential therapeutic targets. <i>BMC Rheumatology</i> , 2017, 1, 2.	0.6	39
78	Interleukin-6 Inhibition in Inflammatory Diseases: Results Achieved and Tasks to Accomplish. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, S20-S28.	1.0	1
79	Association between glucocorticoid therapy and incidence of diabetes mellitus in polymyalgia rheumatica and giant cell arteritis: a systematic review and meta-analysis. <i>RMD Open</i> , 2018, 4, e000521.	1.8	17
80	Magnetic resonance angiography in giant cell arteritis: results of a randomized controlled trial of tocilizumab in giant cell arteritis. <i>Rheumatology</i> , 2018, 57, 982-986.	0.9	84
81	mTOR pathway is activated in endothelial cells from patients with Takayasu arteritis and is modulated by serum immunoglobulin G. <i>Rheumatology</i> , 2018, 57, 1011-1020.	0.9	33
82	A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases. <i>Rheumatology and Therapy</i> , 2018, 5, 21-42.	1.1	97
83	Prognosis and monitoring of giant cell arteritis and associated complications. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 379-388.	1.3	18
84	Tocilizumab for the treatment of giant cell arteritis. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 339-349.	1.3	23
85	Ustekinumab for refractory giant cell arteritis: A prospective 52-week trial. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 523-528.	1.6	69
87	Recent Advances in Giant Cell Arteritis. <i>Current Rheumatology Reports</i> , 2018, 20, 25.	2.1	15
88	Review: What Is the Current Evidence for Disease Subsets in Giant Cell Arteritis?. <i>Arthritis and Rheumatology</i> , 2018, 70, 1366-1376.	2.9	54

#	ARTICLE	IF	CITATIONS
89	Large vessel vasculitides. <i>Medicine</i> , 2018, 46, 112-117.	0.2	3
90	Tocilizumab for the treatment of birdshot uveitis that failed interferon alpha and anti-tumor necrosis factor-alpha therapy: two cases report and literature review. <i>Clinical Rheumatology</i> , 2018, 37, 849-853.	1.0	21
91	Secukinumab for the maintenance of glucocorticoid-free remission in a patient with giant cell arteritis and psoriatic arthritis. <i>Rheumatology</i> , 2018, 57, 934-936.	0.9	18
92	Giant Cell Arteritis: Practical Pearls and Updates. <i>Current Pain and Headache Reports</i> , 2018, 22, 2.	1.3	15
93	Large-vessel involvement and aortic dilation in giant-cell arteritis. A multicenter study of 549 patients. <i>Autoimmunity Reviews</i> , 2018, 17, 391-398.	2.5	97
94	IL-6 expression is correlated with increased T-cell proliferation and survival in the arterial wall in giant cell arteritis. <i>Cardiovascular Pathology</i> , 2018, 33, 55-61.	0.7	7
95	Medications, Therapeutic Modalities, and Regimens Used in the Management of Rheumatic Diseases. , 2018, , 153-175.		1
96	Tocilizumab in Giant Cell Arteritis: A Real-Life Retrospective Study. <i>Angiology</i> , 2018, 69, 763-769.	0.8	13
97	Tocilizumab reduces complement C3 and C4 serum levels in rheumatoid arthritis patients. <i>Clinical Rheumatology</i> , 2018, 37, 1695-1700.	1.0	18
98	Fatal DRESS syndrome under tocilizumab treatment for seronegative polyarthritis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 1048-1049.	2.0	7
99	Treatments for giant cell arteritis: Meta-analysis and assessment of estimates reliability using the fragility index. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 77-82.	1.6	21
100	Interleukin-6: designing specific therapeutics for a complex cytokine. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 395-412.	21.5	440
101	Large-vessel giant cell arteritis: diagnosis, monitoring and management. <i>Rheumatology</i> , 2018, 57, ii32-ii42.	0.9	136
102	Tocilizumab in Giant Cell Arteritis. <i>Cardiology in Review</i> , 2018, 26, 321-330.	0.6	7
103	Tocilizumab in the treatment of giant cell arteritis. <i>Immunotherapy</i> , 2018, 10, 465-472.	1.0	3
104	Ustekinumab inhibits Th1 and Th17 polarisation in a patient with giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, e6-e6.	0.5	24
107	Response to: ustekinumab inhibits Th1 and Th17 polarisation in a giant-cell arteritis patient by Samson et al. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, e7-e7.	0.5	1
108	Current and emerging therapies in large-vessel vasculitis. <i>Rheumatology</i> , 2018, 57, 1513-1524.	0.9	18

#	ARTICLE	IF	CITATIONS
109	Interleukin-6 flags infection in tocilizumab-treated giant cell arteritis. <i>Rheumatology</i> , 2018, 57, 196-197.	0.9	9
110	Incremental Costs in Giant Cell Arteritis. <i>Arthritis Care and Research</i> , 2018, 70, 1074-1081.	1.5	9
112	Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 348-354.	0.5	279
114	Biological treatments in giant cell arteritis & Takayasu arteritis. <i>European Journal of Internal Medicine</i> , 2018, 50, 12-19.	1.0	30
115	Interleukin (IL-6) Immunotherapy. <i>Cold Spring Harbor Perspectives in Biology</i> , 2018, 10, a028456.	2.3	223
118	Pulmonary vasculitis. <i>Journal of Thoracic Disease</i> , 2018, 10, 5560-5575.	0.6	14
119	Update on the epidemiology, risk factors, and outcomes of systemic vasculitides. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 271-294.	1.4	41
120	Biologics in Inflammatory Immune-mediated Systemic Diseases. <i>Current Pharmaceutical Biotechnology</i> , 2018, 18, 1008-1016.	0.9	17
121	Prognosis and future developments in vasculitis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 148-165.	1.4	18
122	Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. <i>Nature Reviews Immunology</i> , 2018, 18, 773-789.	10.6	662
123	Anti-Interleukin-6 Antibody as Treatment for Giant Cell Arteritis. <i>Journal of Neuro-Ophthalmology</i> , 2018, 38, 558-560.	0.4	0
124	IL-6 Blockade and its Therapeutic Success in Giant Cell Arteritis. <i>Journal of Neuro-Ophthalmology</i> , 2018, 38, 551-558.	0.4	3
125	IL-6: To immunity and beyond. <i>Considerations in Medicine</i> , 2018, 2, 19-23.	0.0	0
126	Prevention of glucocorticoid morbidity in giant cell arteritis. <i>Rheumatology</i> , 2018, 57, ii11-ii21.	0.9	34
127	Individual Drugs in Rheumatology and the Risk of Infection. , 2018, , 445-464.		0
128	Immuno-monitoring reveals an extended subclinical disease activity in tocilizumab-treated giant cell arteritis. <i>Rheumatology</i> , 2018, 57, 1795-1801.	0.9	33
129	Profile of tocilizumab and its potential in the treatment of giant cell arteritis. <i>Eye and Brain</i> , 2018, Volume 10, 1-11.	3.8	9
130	Successful treatment with tocilizumab monotherapy for Takayasu arteritis developing during infliximab therapy in a patient with ulcerative colitis. <i>Modern Rheumatology Case Reports</i> , 2018, 2, 174-176.	0.3	4

#	ARTICLE	IF	CITATIONS
131	Tocilizumab as an add-on therapy to glucocorticoids during the first 36 months of treatment of Giant cell arteritis: A prospective study. <i>European Journal of Internal Medicine</i> , 2018, 57, 96-104.	1.0	29
132	Drug therapies for polymyalgia rheumatica: a pharmacotherapeutic update. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1235-1244.	0.9	6
133	Expression and Function of IL12/23 Related Cytokine Subunits (p35, p40, and p19) in Giant-Cell Arteritis Lesions: Contribution of p40 to Th1- and Th17-Mediated Inflammatory Pathways. <i>Frontiers in Immunology</i> , 2018, 9, 809.	2.2	33
134	A Stab in the Dark: A Case Report of an Atypical Presentation of Giant Cell Arteritis (GCA). <i>Geriatrics (Switzerland)</i> , 2018, 3, 36.	0.6	1
135	Primary Care Vasculitis. <i>Primary Care - Clinics in Office Practice</i> , 2018, 45, 305-323.	0.7	4
136	Conventional and biological immunosuppressants in vasculitis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 94-111.	1.4	9
137	Era of steroid sparing in the management of immune-mediated inflammatory diseases. <i>Immunological Medicine</i> , 2018, 41, 6-11.	1.4	13
138	Association of Interleukin 6 Receptor Variant With Cardiovascular Disease Effects of Interleukin 6 Receptor Blocking Therapy. <i>JAMA Cardiology</i> , 2018, 3, 849.	3.0	75
139	Interleukin 12 and interleukin 23 play key pathogenic roles in inflammatory and proliferative pathways in giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1815-1824.	0.5	38
140	Pathogenesis of giant-cell arteritis: how targeted therapies are influencing our understanding of the mechanisms involved. <i>Rheumatology</i> , 2018, 57, ii51-ii62.	0.9	32
141	Current and emerging diagnosis tools and therapeutics for giant cell arteritis. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 593-605.	1.3	17
142	Pathologic Markers Determining Prognosis in Patients With Treated or Healing Giant Cell Arteritis. <i>American Journal of Ophthalmology</i> , 2018, 193, 45-53.	1.7	19
143	Does leflunomide have a role in giant cell arteritis? An open-label study. <i>Clinical Rheumatology</i> , 2019, 38, 291-296.	1.0	44
145	14th EUNOS Congress. <i>Neuro-Ophthalmology</i> , 2019, 43, 1-221.	0.4	2
146	General Principles of Immunotherapy in Neurological Diseases. <i>Contemporary Clinical Neuroscience</i> , 2019, , 387-421.	0.3	3
148	Refractory giant cell arteritis on prednisone and tocilizumab: improvement with subsequent tuberculosis reactivation. <i>Canadian Journal of Ophthalmology</i> , 2019, 54, e192-e194.	0.4	3
149	Body mass index associates with disease relapse in patients with giant cell arteritis. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 1782-1786.	0.9	7
150	Risk of Infections and Cancer in Patients With Rheumatologic Diseases Receiving Interleukin Inhibitors. <i>JAMA Network Open</i> , 2019, 2, e1913102.	2.8	25



#	ARTICLE	IF	CITATIONS
152	Rapid visual recovery following intravenous tocilizumab in glucocorticoid resistant refractory giant cell arteritis. <i>BMJ Case Reports</i> , 2019, 12, e229236.	0.2	8
153	Giant cell arteritis: advances in diagnosis and management. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2019, 80, 448-455.	0.2	0
155	Leveraging Genetic Findings for Precision Medicine in Vasculitis. <i>Frontiers in Immunology</i> , 2019, 10, 1796.	2.2	7
156	Orbital Vasculitidesâ€“Differential Diagnosis. <i>Current Rheumatology Reports</i> , 2019, 21, 54.	2.1	4
158	Serial IL-6 measurements in patients with tocilizumab-treated large-vessel vasculitis detect infections and may predict early relapses. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1012-1014.	0.5	28
159	&lt;p&gt;Giant cell arteritis: early diagnosis is key&lt;/p&gt;. <i>Eye and Brain</i> , 2019, Volume 11, 1-12.	3.8	36
160	Development of an evidence-based regimen of prednisolone to treat giant cell arteritis â€“ the Norwich regimen. <i>Rheumatology Advances in Practice</i> , 2019, 3, rkz001.	0.3	12
162	Different patterns and specific outcomes of large-vessel involvements in giant cell arteritis. <i>Journal of Autoimmunity</i> , 2019, 103, 102283.	3.0	36
163	Giant cell arteritis. <i>BMJ: British Medical Journal</i> , 2019, 365, l1964.	2.4	20
164	Coordination of Immune-Stroma Crosstalk by IL-6 Family Cytokines. <i>Frontiers in Immunology</i> , 2019, 10, 1093.	2.2	84
165	Interleukin-6 does not upregulate pro-inflammatory cytokine expression in an ex vivo model of giant cell arteritis. <i>Rheumatology Advances in Practice</i> , 2019, 3, rkz011.	0.3	7
166	Advances in Therapies and Imaging for Systemic Vasculitis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 1520-1541.	1.1	19
167	Large-Vessel Vasculitis. , 2019, , 609-618.		1
168	New-onset cutaneous sarcoidosis under tocilizumab treatment for giant cell arteritis: a quasi-paradoxical adverse drug reaction. Case report and literature review. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2019, 11, 1759720X1984179.	1.2	19
169	Treatment of giant cell arteritis. <i>Biochemical Pharmacology</i> , 2019, 165, 230-239.	2.0	15
171	2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1160-1166.	0.5	34
173	Glucocorticoid Dosages and Acuteâ€“Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab. <i>Arthritis and Rheumatology</i> , 2019, 71, 1329-1338.	2.9	74
174	Swedish Society of Rheumatology 2018 guidelines for investigation, treatment, and follow-up of giant cell arteritis. <i>Scandinavian Journal of Rheumatology</i> , 2019, 48, 259-265.	0.6	32

#	ARTICLE	IF	CITATIONS
175	Reviewing the Pathophysiology Behind the Advances in the Management of Giant Cell Arteritis. <i>Ophthalmology and Therapy</i> , 2019, 8, 177-193.	1.0	22
176	Treatment of polymyalgia rheumatica. <i>Biochemical Pharmacology</i> , 2019, 165, 221-229.	2.0	17
177	Risk of relapse after discontinuation of tocilizumab therapy in giant cell arteritis. <i>Rheumatology</i> , 2019, 58, 1639-1643.	0.9	68
178	Pseudo-polyarthrite rhizomélique et artérite à cellules géantes en 2019. <i>Revue Du Rhumatisme Monographies</i> , 2019, 86, 199-206.	0.0	3
179	The Treatment of Giant Cell Arteritis in Different Clinical Settings. <i>Frontiers in Immunology</i> , 2019, 9, 3129.	2.2	17
180	Current advances in the treatment of giant cell arteritis: the role of biologics. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2019, 11, 1759720X1982722.	1.2	9
182	Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis. <i>RMD Open</i> , 2019, 5, e001003.	1.8	52
183	Neuro-Ophthalmologic Complications of Giant Cell Arteritis: Diagnosis and Treatment. <i>Seminars in Neurology</i> , 2019, 39, 673-681.	0.5	9
184	Significant association between clinical characteristics and changes in peripheral immuno-phenotype in large vessel vasculitis. <i>Arthritis Research and Therapy</i> , 2019, 21, 304.	1.6	27
185	Mast Cell Degranulation Decreases Lipopolysaccharide-Induced Aortic Gene Expression and Systemic Levels of Interleukin-6 In Vivo. <i>Mediators of Inflammation</i> , 2019, 2019, 1-7.	1.4	2
187	Vasculitis research: Current trends and future perspectives. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 10-20.	0.9	10
188	Main Oral Manifestations in Immune-Mediated and Inflammatory Rheumatic Diseases. <i>Journal of Clinical Medicine</i> , 2019, 8, 21.	1.0	28
189	Targets of monoclonal antibodies for immunological diseases. <i>Archives of Pharmacal Research</i> , 2019, 42, 293-304.	2.7	4
190	Pathophysiology of large vessel vasculitis and utility of interleukin-6 inhibition therapy. <i>Modern Rheumatology</i> , 2019, 29, 287-293.	0.9	41
191	The therapeutic potential of tuftsin-phosphorylcholine in giant cell arteritis. <i>Journal of Autoimmunity</i> , 2019, 98, 113-121.	3.0	7
192	Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 126-135.	1.6	66
193	Pathogenesis of large vessel vasculitis: Implications for disease classification and future therapies. <i>Vascular Medicine</i> , 2019, 24, 79-88.	0.8	26
194	Current options and recommendations for the treatment of thoracic aortic pathologies involving the aortic arch: an expert consensus document of the European Association for Cardio-Thoracic surgery (EACTS) and the European Society for Vascular Surgery (ESVS). <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 55, 133-162.	0.6	349

#	ARTICLE	IF	CITATIONS
195	Granuloma annulare development in a patient with rheumatoid arthritis treated with tocilizumab: case-based review. <i>Rheumatology International</i> , 2019, 39, 353-357.	1.5	12
196	The role of biologics in the treatment of giant cell arteritis. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 65-72.	1.4	6
197	Management of large-vessel vasculitis. <i>Current Opinion in Rheumatology</i> , 2019, 31, 25-31.	2.0	14
198	Editor's Choice "Current Options and Recommendations for the Treatment of Thoracic Aortic Pathologies Involving the Aortic Arch: An Expert Consensus Document of the European Association for Cardio-Thoracic Surgery (EACTS) & the European Society for Vascular Surgery (ESVS). <i>European Journal of Vascular and Endovascular Surgery</i> , 2019, 57, 165-198.	0.8	204
199	Diagnosis and management of giant cell arteritis: an Asia-Pacific perspective. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 28-40.	0.9	9
200	Cytokine targeting in rheumatoid arthritis. <i>Clinical Immunology</i> , 2019, 206, 3-8.	1.4	16
201	Takayasu arteritis and giant cell arteritis: are they a spectrum of the same disease?. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 41-48.	0.9	41
202	Disease progression of Takayasu arteritis in two patients treated with tocilizumab. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e21-e21.	0.5	15
203	Prevalence of Giant Cell Arteritis Relapse in Patients Treated With Glucocorticoids: A Meta-Analysis. <i>Arthritis Care and Research</i> , 2020, 72, 838-849.	1.5	62
204	Effect of Treatment on Imaging, Clinical, and Serologic Assessments of Disease Activity in Large-vessel Vasculitis. <i>Journal of Rheumatology</i> , 2020, 47, 99-107.	1.0	48
205	Elevated cerebrospinal fluid levels of total protein in patients with secondary central nervous system vasculitis and giant cell arteritis. <i>Modern Rheumatology</i> , 2020, 30, 1033-1038.	0.9	1
206	2018 Update of the EULAR recommendations for the management of large vessel vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 19-30.	0.5	667
207	Characteristics and management of giant cell arteritis in France: a study based on national health insurance claims data. <i>Rheumatology</i> , 2020, 59, 120-128.	0.9	17
208	Patterns of Arterial Disease in Takayasu Arteritis and Giant Cell Arteritis. <i>Arthritis Care and Research</i> , 2020, 72, 1615-1624.	1.5	77
209	The diagnosis and management of temporal arteritis. <i>Australasian journal of optometry</i> , The, 2020, 103, 572-582.	0.6	11
210	Autoimmune and Autoantibody-Associated Encephalomyelopathies. , 2020, , 1067-1114.		1
211	Articrite "cellules gantes": de la physiopathologie aux nouvelles cibles thérapeutiques. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2020, 204, 18-28.	0.0	0
212	Should Tocilizumab Be Used Routinely in New Patients With a Diagnosis of Giant Cell Arteritis?. <i>Journal of Neuro-Ophthalmology</i> , 2020, 40, 117-121.	0.4	4

#	ARTICLE	IF	CITATIONS
213	Outcome Measures in Large Vessel Vasculitis: Relationship Between Patientâ€™, Physicianâ€™, Imagingâ€™, and Laboratoryâ€™Based Assessments. <i>Arthritis Care and Research</i> , 2020, 72, 1296-1304.	1.5	23
214	The Role of Multimodality Imaging in Monitoring Disease Activity and Therapeutic Response to Tocilizumab in Giant Cell Arteritis. <i>Mediators of Inflammation</i> , 2020, 2020, 1-9.	1.4	6
215	An overview of the perspectives on experimental models and new therapeutic targets in giant cell arteritis. <i>Autoimmunity Reviews</i> , 2020, 19, 102636.	2.5	4
216	Treatment of Giant Cell Arteritis and Takayasu Arteritisâ€™Current and Future. <i>Current Rheumatology Reports</i> , 2020, 22, 84.	2.1	19
217	Reducing the Toxicity of Long-Term Glucocorticoid Treatment in Large Vessel Vasculitis. <i>Current Rheumatology Reports</i> , 2020, 22, 85.	2.1	9
219	Update der EULAR-Empfehlungen zum Management der GroÃŸgefÃŸvaskulitis mit Fokus auf Riesenzellarteriitis. <i>Karger Kompass Autoimmun</i> , 2020, 2, 6-9.	0.0	0
220	Efficacy and safety of tocilizumab in giant cell arteritis: a single centre NHS experience using imaging (ultrasound and PET-CT) as a diagnostic and monitoring tool. <i>RMD Open</i> , 2020, 6, e001417.	1.8	24
222	Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica. <i>Nature Reviews Rheumatology</i> , 2020, 16, 481-495.	3.5	54
223	Treating COVID-19: Review of Drug Hypersensitivity Reactions. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2020, 30, 385-399.	0.6	7
224	Certain perspectives about the use of corticosteroids for managing hospitalized patients with rheumatic diseases. <i>Clinical Rheumatology</i> , 2020, 39, 3131-3136.	1.0	4
225	Interstitial granulomatous dermatitis following tocilizumab, a paradoxical reaction?. <i>Dermatologic Therapy</i> , 2020, 33, e14207.	0.8	6
226	A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Giant Cell Arteritis. <i>Rheumatology and Therapy</i> , 2020, 7, 793-810.	1.1	30
227	Polymyalgia Rheumatica and Giant Cell Arteritis. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 993.	3.8	34
228	Treatment strategy introducing immunosuppressive drugs with glucocorticoids ab initio or very early in giant cell arteritis: A multicenter retrospective controlled study. <i>Journal of Translational Autoimmunity</i> , 2020, 3, 100072.	2.0	5
230	Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19: An EAACI Position Paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2775-2793.	2.7	23
231	Cytomegalovirus Retinitis in a Patient Taking Tocilizumab: A Case Report. <i>Journal of Vitreoretinal Diseases</i> , 2020, 4, 233-235.	0.2	0
232	European Headache Federation recommendations for neurologists managing giant cell arteritis. <i>Journal of Headache and Pain</i> , 2020, 21, 28.	2.5	31
233	Cytomegalovirus Retinal Necrosis With Occlusive Vasculopathy Secondary to Steroid Immunosuppression for Giant Cell Arteritis. <i>Journal of Vitreoretinal Diseases</i> , 2020, 4, 227-232.	0.2	1

#	ARTICLE	IF	CITATIONS
234	Tocilizumab treatment effectively improves coronary artery involvement in patients with Takayasu arteritis. <i>Clinical Rheumatology</i> , 2020, 39, 2369-2378.	1.0	21
235	Drug repurposing in cardiovascular diseases: Opportunity or hopeless dream?. <i>Biochemical Pharmacology</i> , 2020, 177, 113894.	2.0	8
236	&lt;p&gt;Giant Cell Arteritis: The Experience of Two Collaborative Referral Centers and an Overview of Disease Pathogenesis and Therapeutic Advancements&lt;p&gt;. <i>Clinical Ophthalmology</i> , 2020, Volume 14, 775-793.	0.9	13
237	Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2093011.	1.2	23
239	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. <i>Rheumatology</i> , 2020, 59, 487-494.	0.9	56
240	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. <i>Rheumatology</i> , 2020, 59, e1-e23.	0.9	128
241	JCS 2017 Guideline on Management of Vasculitis Syndromeâ€œâ€• Digest Version â€œ. <i>Circulation Journal</i> , 2020, 84, 299-359.	0.7	59
242	Treatment of giant-cell arteritis: from broad spectrum immunosuppressive agents to targeted therapies. <i>Rheumatology</i> , 2020, 59, iii17-iii27.	0.9	9
243	Recent advances in the diagnosis and management of giant cell arteritis. <i>Current Opinion in Rheumatology</i> , 2020, 32, 201-207.	2.0	24
244	Tocilizumab for Giant Cell Arteritis. <i>International Ophthalmology Clinics</i> , 2020, 60, 57-62.	0.3	14
245	Translating IL-6 biology into effective treatments. <i>Nature Reviews Rheumatology</i> , 2020, 16, 335-345.	3.5	369
246	Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based preventionÂstrategy. <i>Annals of Oncology</i> , 2020, 31, 724-744.	0.6	129
247	Ustekinumab for the Treatment of Giant Cell Arteritis. <i>Arthritis Care and Research</i> , 2021, 73, 893-897.	1.5	41
248	Reply. <i>Arthritis Care and Research</i> , 2021, 73, 1057-1058.	1.5	2
249	Practice points for ophthalmologists from the 2020 British Society for Rheumatology Giant Cell Arteritis guidelines. <i>Eye</i> , 2021, 35, 699-701.	1.1	5
250	COVID-19: A review of therapeutic strategies and vaccine candidates. <i>Clinical Immunology</i> , 2021, 222, 108634.	1.4	180
251	Temporal Arteritis Revealing Antineutrophil Cytoplasmic Antibodyâ€œAssociated Vasculitides: A Caseâ€œControl Study. <i>Arthritis and Rheumatology</i> , 2021, 73, 286-294.	2.9	25
252	Use of 18F-fluorodeoxyglucose positron emission tomography to monitor tocilizumab effect on vascular inflammation in giant cell arteritis. <i>Rheumatology</i> , 2021, 60, 4384-4389.	0.9	34

#	ARTICLE	IF	CITATIONS
254	Management of primary vasculitides with biologic and novel small molecule medications. <i>Current Opinion in Rheumatology</i> , 2021, 33, 8-14.	2.0	1
255	One Giant Step for Giant Cell Arteritis: Updates in Diagnosis and Treatment. <i>Current Treatment Options in Neurology</i> , 2021, 23, 6.	0.7	18
257	Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations. <i>Arthritis Research and Therapy</i> , 2021, 23, 8.	1.6	33
258	Improvement of Treg immune response after treatment with tocilizumab in giant cell arteritis. <i>Clinical and Translational Immunology</i> , 2021, 10, e1332.	1.7	18
259	Co-occurrence of unclassified myeloproliferative neoplasm and giant cell arteritis in a patient treated with allogeneic hematopoietic stem cell transplantation: a case report and literature review. <i>Central-European Journal of Immunology</i> , 2021, 46, 121-126.	0.4	1
260	Treatment Patterns, Disease Burden, and Outcomes in Patients with Giant Cell Arteritis and Polymyalgia Rheumatica: A Real-World, Electronic Health Record-Based Study of Patients in Clinical Practice. <i>Rheumatology and Therapy</i> , 2021, 8, 529-539.	1.1	2
261	Joint Statement (DZK, DGRh, DDG) on the Tuberculosis Risk with Treatment Using Novel Non-TNF-Alpha Biologicals. <i>Pneumologie</i> , 2021, 75, 293-303.	0.1	3
262	The Immunopathology of Giant Cell Arteritis Across Disease Spectra. <i>Frontiers in Immunology</i> , 2021, 12, 623716.	2.2	30
263	Real-world Risk of Relapse of Giant Cell Arteritis Treated With Tocilizumab: A Retrospective Analysis of 43 Patients. <i>Journal of Rheumatology</i> , 2021, 48, 1435-1441.	1.0	12
264	Update on the Treatment of Giant Cell Arteritis and Polymyalgia Rheumatica. <i>Medical Clinics of North America</i> , 2021, 105, 311-324.	1.1	4
266	Vision loss in patients with giant cell arteritis treated with tocilizumab. <i>Arthritis Research and Therapy</i> , 2021, 23, 92.	1.6	14
267	Giant Cell Arteritis: A Systematic Review and Meta-Analysis of Test Accuracy and Benefits and Harms of Common Treatments. <i>ACR Open Rheumatology</i> , 2021, 3, 429-441.	0.9	20
268	Giant cell arteritis with ocular involvement successfully treated with tocilizumab and very short-course glucocorticoids: A case report. <i>Journal Francais D'Ophthalmologie</i> , 2021, 44, 481-484.	0.2	3
269	Tocilizumab vs placebo for the treatment of giant cell arteritis with polymyalgia rheumatica symptoms, cranial symptoms or both in a randomized trial. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 469-476.	1.6	23
270	Arteritic anterior ischaemic optic neuropathy: An update. <i>European Journal of Ophthalmology</i> , 2021, 31, 2818-2827.	0.7	10
271	Tocilizumab in refractory giant cell arteritis. Monotherapy versus combined therapy with conventional immunosuppressive drugs. Observational multicenter study of 134 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 387-394.	1.6	13
273	The management of large vessel vasculitides. <i>Beyond Rheumatology</i> , 2021, 3, .	0.3	0
274	Giant cell arteritis: A nationwide, population-based cohort study on incidence, diagnostic imaging, and glucocorticoid treatment. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 360-366.	1.6	15

#	ARTICLE	IF	CITATIONS
275	Characterization of Extracranial Giant Cell Arteritis with Intracranial Involvement and its Rapidly Progressive Subtype. <i>Annals of Neurology</i> , 2021, 90, 118-129.	2.8	10
277	The role of IL-6 and IL-6 blockade in COVID-19. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 601-618.	1.3	62
278	Tocilizumab in patients with giant cell arteritis: for whom and for how long?. <i>Lancet Rheumatology</i> , The, 2021, 3, e314-e315.	2.2	0
279	An Insight into Giant Cell Arteritis Pathogenesis: Evidence for Oxidative Stress and SIRT1 Downregulation. <i>Antioxidants</i> , 2021, 10, 885.	2.2	7
280	Current and innovative therapeutic strategies for the treatment of giant cell arteritis. <i>Expert Opinion on Orphan Drugs</i> , 2021, 9, 161-173.	0.5	4
282	Treatment failure in giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1467-1474.	0.5	20
283	The long-term use of tocilizumab in giant cell arteritis. <i>Rheumatology</i> , 2021, 60, 4447-4449.	0.9	1
284	My Treatment Approach to Giant Cell Arteritis. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1530-1545.	1.4	12
285	Giant Cell Arteritis: Real-life Experience. <i>Journal of Rheumatology</i> , 2021, 48, 1354-1354.	1.0	2
286	Efficacy and safety of steroid-sparing treatments in giant cell arteritis according to the glucocorticoids tapering regimen: A systematic review and meta-analysis. <i>European Journal of Internal Medicine</i> , 2021, 88, 96-103.	1.0	12
287	Vasculitis: From Target Molecules to Novel Therapeutic Approaches. <i>Biomedicines</i> , 2021, 9, 757.	1.4	3
288	Quantitative ultrasound to monitor the vascular response to tocilizumab in giant cell arteritis. <i>Rheumatology</i> , 2021, 60, 5052-5059.	0.9	25
289	Giant cell arteritis: what is new in the preclinical and early clinical development pipeline?. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 921-932.	1.9	4
290	Practical management of patients on anti-IL6R therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI). <i>Joint Bone Spine</i> , 2021, 88, 105221.	0.8	0
291	Vasculitis therapy refines vasculitis mechanistic classification. <i>Autoimmunity Reviews</i> , 2021, 20, 102829.	2.5	13
292	Tocilizumab for the treatment of non-critical COVID-19 pneumonia: an overview of the rationale and clinical evidence to date. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 1279-1287.	1.3	4
293	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 1349-1365.	2.9	231
294	Dermatological manifestations associated with COVID-19: A comprehensive review of the current knowledge. <i>Journal of Medical Virology</i> , 2021, 93, 5756-5767.	2.5	26

#	ARTICLE	IF	CITATIONS
295	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. <i>Arthritis Care and Research</i> , 2021, 73, 1071-1087.	1.5	61
296	COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies. <i>Biomolecules</i> , 2021, 11, 993.	1.8	136
297	2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. <i>Stroke</i> , 2021, 52, e364-e467.	1.0	1,123
298	Tocilizumab for giant cell arteritis. <i>The Cochrane Library</i> , 2021, 2021, CD013484.	1.5	7
299	Epidemiology of major relapse in giant cell arteritis: A study-level meta-analysis. <i>Autoimmunity Reviews</i> , 2022, 21, 102930.	2.5	13
300	Risks and benefits of tocilizumab monotherapy in giant cell arteritis. <i>Lancet Rheumatology</i> , The, 2021, 3, e606-e607.	2.2	0
301	Glucocorticoid dosing and relapses in giant cell arteritis—a single centre cohort study. <i>Rheumatology</i> , 2022, 61, 1997-2005.	0.9	5
302	Tocilizumab monotherapy after ultra-short glucocorticoid administration in giant cell arteritis: a single-arm, open-label, proof-of-concept study. <i>Lancet Rheumatology</i> , The, 2021, 3, e619-e626.	2.2	25
303	The mosaic of autoimmunity - A taste for more. The 12th international congress of autoimmunity 2021 (AUTO12) virtual. <i>Autoimmunity Reviews</i> , 2021, 20, 102945.	2.5	11
304	An update on the pathogenic role of IL-6 in rheumatic diseases. <i>Cytokine</i> , 2021, 146, 155645.	1.4	11
305	Ocular Manifestations of Systemic Vasculitides. , 2021, , 1-48.		0
306	Coronary artery vasculitis: a review of current literature. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 7.	0.7	21
307	Biologic Therapies for Giant Cell Arteritis. <i>Biologics: Targets and Therapy</i> , 2021, Volume 15, 17-29.	3.0	7
308	Temporal artery ultrasound versus temporal artery biopsy for giant cell arteritis. <i>The Cochrane Library</i> , 0, , .	1.5	2
310	Relapses in three patients with Takayasu arteritis under tocilizumab treatment detected by contrast enhanced ultrasound. <i>Vasa - European Journal of Vascular Medicine</i> , 2018, 47, 149-152.	0.6	11
313	Tocilizumab in Large Vessel Vasculitis – Different Routes of Administration. <i>Open Rheumatology Journal</i> , 2018, 12, 152-159.	0.1	3
314	Giant cell arteritis: An updated review of an old disease. <i>Cleveland Clinic Journal of Medicine</i> , 2019, 86, 465-472.	0.6	8
315	Multicenter, Open-Label, Phase I/II Study of Tocilizumab, an Anti-Interleukin-6 Receptor Monoclonal Antibody, Combined with Gemcitabine in Patients with Advanced Pancreatic Cancer. <i>Journal of Medical Diagnostic Methods</i> , 2017, 06, .	0.0	5





#	ARTICLE	IF	CITATIONS
338	A Clinical Update on Employing Tocilizumab to Fight COVID-19. , 0, , .		0
339	Internal Medicine, 2020, 109, 1828-1835.	0.0	0
340	Tocilizumab or glucocorticoids treatment for patients with SARS-CoV-2 pneumonia: An observational study. Brazilian Journal of Infectious Diseases, 2022, 26, 101702.	0.3	0
342	Temporal Artery Vascular Diseases. Journal of Clinical Medicine, 2022, 11, 275.	1.0	7
343	Blocking GM-CSF receptor $\hat{\pm}$ with mavrilimumab reduces infiltrating cells, pro-inflammatory markers and neoangiogenesis in ex vivo cultured arteries from patients with giant cell arteritis. Annals of the Rheumatic Diseases, 2022, 81, 524-536.	0.5	26
344	From Active to Non-active Giant Cell Arteritis: Longitudinal Monitoring of Patients on Glucocorticoid Therapy in Combination With Leflunomide. Frontiers in Medicine, 2021, 8, 827095.	1.2	7
345	Application of IL-6 antagonists in autoimmune disorders. , 2022, , 83-114.		0
347	The Italian Society of Rheumatology clinical practice guidelines for the management of large vessel vasculitis. Reumatismo, 2021, 73, .	0.4	2
348	Need and value of targeted immunosuppressive therapy in giant cell arteritis. RMD Open, 2022, 8, e001652.	1.8	6
349	Tocilizumab for the treatment of giant cell arteritis in Scotland: a report on behalf of the Scottish Society for Rheumatology standards subgroup. Rheumatology Advances in Practice, 2022, 6, rkac017.	0.3	4
350	Self-monitoring of the resting heart rate using a fitness tracker smartwatch application leads to an early diagnosis of large vessel vasculitis. BMJ Case Reports, 2022, 15, e245021.	0.2	2
351	Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study. Annals of the Rheumatic Diseases, 2022, 81, 861-867.	0.5	35
352	Advances in the Treatment of Giant Cell Arteritis. Journal of Clinical Medicine, 2022, 11, 1588.	1.0	11
353	Giant Cell Arteritis: Updates and Controversies. Frontiers in Ophthalmology, 2022, 2, .	0.2	1
354	Treatment of Giant Cell Arteritis (GCA). Journal of Clinical Medicine, 2022, 11, 1799.	1.0	7
355	Update on the Treatment of Giant Cell Arteritis and Polymyalgia Rheumatica. Rheumatic Disease Clinics of North America, 2022, 48, 493-506.	0.8	2
356	Large-vessel vasculitis. Nature Reviews Disease Primers, 2021, 7, 93.	18.1	74
358	The Th17 Pathway in Vascular Inflammation: Culprit or Consort?. Frontiers in Immunology, 2022, 13, 888763.	2.2	16

#	ARTICLE	IF	CITATIONS
359	Cell transcriptomic atlas of the non-human primate <i>Macaca fascicularis</i> . <i>Nature</i> , 2022, 604, 723-731.	13.7	81
364	Ocular Manifestations of Systemic Vasculitides. , 2022, , 7449-7495.		0
365	Noninfectious Orbital Inflammations. , 2022, , 5133-5172.		0
366	Retinal Manifestations of the Rheumatic Diseases. , 2022, , 4227-4262.		0
367	Tocilizumab for giant cell arteritis. <i>The Cochrane Library</i> , 2022, 2022, CD013484.	1.5	1
369	Does Tocilizumab Influence Ophthalmic Outcomes in Giant Cell Arteritis?. <i>Journal of Neuro-Ophthalmology</i> , 2022, 42, 173-179.	0.4	2
370	Review of guideline for the management of large vessel vasculitis presented in 2021 by the American College of Rheumatology / Vasculitis Foundation. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2022, 60, 165-173.	0.2	1
371	Looking ahead: giant-cell arteritis in 10 years time. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2210963.	1.2	10
372	The Sound of Interconnectivity; The European Vasculitis Society 2022 Report. <i>Kidney International Reports</i> , 2022, 7, 1745-1757.	0.4	3
373	New Insights into the Pathogenesis of Giant Cell Arteritis: Mechanisms Involved in Maintaining Vascular Inflammation. <i>Journal of Clinical Medicine</i> , 2022, 11, 2905.	1.0	10
374	The 100 Most-Cited Papers on Giant Cell Arteritis: A Bibliometric Analysis. <i>Current Rheumatology Reviews</i> , 2023, 19, 122-133.	0.4	1
375	Intravenous tocilizumab for the treatment of giant cell arteritis: a phase Ib dose-ranging pharmacokinetic bridging study. <i>Arthritis Research and Therapy</i> , 2022, 24, .	1.6	3
376	Comparing treatment options for large vessel vasculitis. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 793-805.	1.3	7
377	Lessons learned from the preclinical discovery and development of sarilumab for the treatment of rheumatoid arthritis. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 799-813.	2.5	3
378	Efficacy and Safety of Tocilizumab in the Treatment of Ocular Manifestations in Giant Cell Arteritis. <i>Advances in Ophthalmology and Optometry</i> , 2022, , .	0.3	0
379	Management of ocular arterial ischemic diseases: a review. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2023, 261, 1-22.	1.0	3
380	Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, 773-787.	0.5	11
381	Treatment of giant cell arteritis - current approach and new possibilities. <i>Vnitri Lekarstvi</i> , 2022, 68, 266-272.	0.1	0

#	ARTICLE	IF	CITATIONS
382	Indirect Comparison of Glucocorticoid-Sparing Agents for Remission Maintenance in Giant Cell Arteritis: A Network Meta-analysis. <i>Mayo Clinic Proceedings</i> , 2022, 97, 1824-1835.	1.4	3
383	The innate face of Giant Cell Arteritis: Insight into cellular and molecular innate immunity pathways to unravel new possible biomarkers of disease. <i>Frontiers in Molecular Medicine</i> , 0, 2, .	0.6	2
384	Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patients. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2211137.	1.2	6
385	Duration of Treatment With Glucocorticoids in Giant Cell Arteritis. <i>Journal of Clinical Rheumatology</i> , 0, Publish Ahead of Print, .	0.5	1
386	Evidence-based Role of Aspirin in Giant Cell Arteritis: A Literature Review. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2022, 12, 11-16.	0.4	1
387	Neuropharmacology in the Intensive Care Unit. <i>Critical Care Clinics</i> , 2022, , .	1.0	0
388	Cutaneous Adverse Reactions to Biologic Agents. <i>Updates in Clinical Dermatology</i> , 2022, , 283-302.	0.1	0
389	Pan American League of Associations for Rheumatology guidelines for the treatment of giant cell arteritis. <i>Lancet Rheumatology</i> , The, 2022, 4, e864-e872.	2.2	3
390	Measurement Properties of Outcome Instruments for Large-Vessel Vasculitis: A Systematic Literature Review. <i>Journal of Rheumatology</i> , 2023, 50, 789-798.	1.0	3
391	Giant cell arteritis: Update on clinical manifestations, diagnosis, and management. <i>European Journal of Internal Medicine</i> , 2023, 107, 17-26.	1.0	8
392	Epidemiology and predictors of relapse in giant cell arteritis: A systematic review and meta-analysis. <i>Joint Bone Spine</i> , 2023, 90, 105494.	0.8	4
393	Immunosuppressive Therapy in Giant Cell Arteritis: Do Steroids Still Reign Supreme?. , 2022, 16, 85.		0
395	Tocilizumab-Induced Dermatitis in a Patient With Rheumatoid Arthritis. <i>Cureus</i> , 2022, , .	0.2	0
396	Metabolic bone health considerations in giant cell arteritis and polymyalgia rheumatica. <i>Women's Health</i> , 2023, 19, 174550572211473.	0.7	0
397	Management of Patients Affected by Giant Cell Arteritis during the COVID-19 Pandemic: Telemedicine Protocol TELEMCOV. <i>Journal of Personalized Medicine</i> , 2023, 13, 620.	1.1	0
398	Management of giant-cell arteritis in Switzerland: an online national survey. <i>Swiss Medical Weekly</i> , 2023, 153, 40051.	0.8	0
399	Systematic review and meta-analysis of the current literature on tocilizumab in patients with refractory Takayasu arteritis. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
400	Giant cell arteritis: reviewing the advancing diagnostics and management. <i>Eye</i> , 2023, 37, 2365-2373.	1.1	7

#	ARTICLE	IF	CITATIONS
401	What is a response in randomised controlled trials in giant cell arteritis?. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, 897-900.	0.5	5
402	Myelomonocytic cells in giant cell arteritis activate trained immunity programs sustaining inflammation and cytokine production. <i>Rheumatology</i> , 2023, 62, 3469-3479.	0.9	1
403	Human monocyte-derived suppressive cells (HuMoSC) for cell therapy in giant cell arteritis. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	4
405	Unmet need in the treatment of polymyalgia rheumatica and giant cell arteritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2022, 36, 101822.	1.4	1
406	Tocilizumab in giant cell arteritis: an update for the clinician. <i>Current Opinion in Rheumatology</i> , 2023, 35, 135-140.	2.0	0
407	Treatment of Giant Cell Arteritis. <i>International Ophthalmology Clinics</i> , 2023, 63, 39-54.	0.3	0
408	Pilot study of tocilizumab monotherapy for active chronic periaortitis. <i>RMD Open</i> , 2023, 9, e003007.	1.8	0
409	Giant Cell Arteritis and Polymyalgia Rheumatica. , 2023, , 417-446.		0
410	Outcomes during and after long-term tocilizumab treatment in patients with giant cell arteritis. <i>RMD Open</i> , 2023, 9, e002923.	1.8	2
412	Atteintes coronariennes et artÃ©rite a cellules gÃ©antes: Ã propos de 2Ã©cas et revue de la littÃ©rature. <i>Revue De Medecine Interne</i> , 2023, 44, 394-401.	0.6	0
416	Pulmonary Vasculitides. , 2023, , 711-762.		0
430	Anteriore ischÃ©mische Optikusneuropathie (AION). <i>Springer Reference Medizin</i> , 2023, , 1-16.	0.0	1
437	Cytokine storm and translating IL-6 biology into effective treatments for COVID-19. <i>Frontiers of Medicine</i> , 2023, 17, 1080-1095.	1.5	0
446	Giant cell arteritisâ€“associated ocular vascular diseases. , 2024, , 495-506.		0